A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to
investigate the effect of itraconazole and rifampin on the PK of vemurafenib following
multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable
Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other
malignant tumor types that harbor a V600-activating mutation of BRAF where the participant
has no acceptable standard treatment options.